Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 456,997	$ 526,423
Prepaid expenses and other current assets	19,903	11,406
Research and development incentives receivable	39,062	24,039
Total current assets	515,962	561,868
Property and equipment, net	12,788	14,515
Operating lease right-of-use assets	12,025	13,169
Other assets	6,368	5,792
Total assets	547,143	595,344
Current liabilities:
Accounts payable	7,061	13,050
Accrued expenses and other current liabilities	26,029	31,509
Deferred revenue, current portion	16,420	24,978
Total current liabilities	49,510	69,537
Long-term debt, net of discount	30,802	30,698
Operating lease liabilities, net of current portion	8,048	9,382
Deferred revenue, net of current portion	98,127	110,216
Other long-term liabilities	4,608	4,579
Total liabilities	191,095	224,412
Commitments and contingencies (Note 11)
Shareholders' equity:
Ordinary shares, including non-voting ordinary shares, £0.01 nominal value; 61,876,165 and 59,612,613 shares authorized on March 31, 2024 and December 31, 2023, respectively; 42,632,597 and 42,431,766 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	553	550
Additional paid-in capital	894,596	883,446
Accumulated other comprehensive loss	(778)	(1,304)
Accumulated deficit	(538,323)	(511,760)
Total shareholders' equity	356,048	370,932
Total liabilities and shareholders' equity	$ 547,143	$ 595,344